All In Biotech

Drug Trial Radar · NCT05967117

Chest CT Using Low-concentration Iodine Contrast Media

Chest CT Using Low-concentration Iodine Contrast Media - a Prospective Multicenter Comparative Study

Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

370

Planned (sponsor's estimate)

Start

Nov 24, 2023

Primary completion

Nov 2024

Study completion Nov 2024

Sponsor

Lead sponsor
Jung Im JungAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Taejoon Pharmaceutical Co., Ltd.
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging. The primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.

Conditions

  • Pulmonary Disease

Interventions

  • Iohexol (320mgI/mL) with 120kVpDrug

    Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

  • Iohexol (320mgI/mL) with 100kVpDrug

    Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

  • Iohexol (270mgI/mL) with 100kVpDrug

    Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

  • Iohexol (240mgI/mL) with 100kVpDrug

    Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anatomic depiction (including image sharpness)Time frame: 12 months after the CT scan (Chest contrast-enhanced CT is a 1-day procedure, but evaluating all the images will be done one year after the 1st CT scan.)
  2. NoiseTime frame: 12 months after the CT scan
  3. Contrast-related artifactTime frame: 12 months after the CT scan
  4. Overall diagnostic acceptabilityTime frame: 12 months after the CT scan

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Chonnam National University Hospital

    Gwangju, South Korea · Completed

  • Seoul National University Hospital

    Seoul, South Korea · Completed

  • Bucheon St. Mary's Hospital, The Catholic University of Korea

    Bucheon-si, Gyeonggi-do, South Korea · Completed

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, South Korea · Recruiting

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea · Recruiting

  • Seoul St. Mary's Hospital, The Catholic University of Korea

    Seoul, Seocho-gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.